Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 5/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | INSR | P06213 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 3/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448330 | 0.94 | AXL (0.36) | AXLEGFRNR3C1JAK3NTRK1 | |
| SCHEMBL3448462 | 0.92 | SYK (0.38) | AXLEGFRMET | |
| SCHEMBL3451798 | 0.91 | EGFR (0.36) | AXLEGFRNR3C1JAK3INSR | |
| SCHEMBL3447146 | 0.87 | RAF1 (0.37) | AXLEGFRTYRO3 | |
| SCHEMBL3454800 | 0.86 | SYK (0.42) | AXLEGFR | |
| SCHEMBL3447261 | 0.86 | EGFR (0.36) | AXLEGFRTYRO3 | |
| SCHEMBL3450256 | 0.84 | EGFR (0.37) | AXLEGFRNR3C1JAK3INSR | |
| SCHEMBL3448591 | 0.84 | EGFR (0.38) | EGFRJAK3INSRMET | |
| SCHEMBL3449652 | 0.84 | EGFR (0.39) | AXLEGFRJAK3TYRO3 | |
| SCHEMBL3448528 | 0.84 | EGFR (0.41) | EGFRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | AXL 2812/4885EGFR 2771/4885NR3C1 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.